NCT03912766

Serum Copeptin as a Predictor of the Risk of Hyponatremia After Transurethral Prostatectomy

Completed Last updated 11 April 2019

What this trial tests

trial testing serum copeptin in Benign Prostatic Hyperplasia in 43 participants. Completed in 30 March 2018.

Timeline

1 February 2016

Primary endpoint
2 January 2017

30 March 2018

Quick facts

Lead sponsor	Medical University of Lodz
Status	Completed
Study type	OBSERVATIONAL
Enrollment	43
Start date	1 February 2016
Primary completion	2 January 2017
Estimated completion	30 March 2018
Sites	1 location across Poland

Drugs / interventions tested

• serum copeptin

Conditions studied

• Benign Prostatic Hyperplasia — all drugs for Benign Prostatic Hyperplasia →

Sponsor

Medical University of Lodz

Who can join

Adults 40 to 80, male only, with Benign Prostatic Hyperplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hyponatremic hypovolemia is a frequent complication of transurethral resection of the prostate gland (TURP). Copeptin has been established as is a surrogate marker of vasopressin and is measured useful for thea clinical assessment of various sodium and water disturbances. The aim of our the study was to assess the utility of serum concentration of copeptin (CPP) and brain natriuretic peptide (NT-proBNP) for the prediction of postoperative alterations of serum sodium concentration. Study population comprised 43 patients with benign prostatic hyperplasia (BPH) undergoing transurethral resection of the prostate gland. In a forward stepwise multiple regression only serum copeptin before the surgery and the duration of TURP significantly explained the variation of sodium concentration for 12 hours from the start of the surgery. Serum NT-proBNP before the surgery did not predict hyponatremia 12 hours after TURP.Conclusion Serum copeptin before TURP surgery but not NT-proBNP may be a clinically useful marker of a decrease of serum sodium after TURP surgery.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Serum copeptin as a predictor of risk of hyponatremia after transurethral prostatectomy.
   Bryc-Walczak K, Bryc W, Nowicki M. · · 2023 · PMID 37037484 · DOI 10.23876/j.krcp.21.143